

## Special Issue

# 10th Anniversary of Biomedicines – Therapeutic Targeting of Cellular Quality Control Mechanisms in Chronic Lung Diseases

### Message from the Guest Editor

Efforts to understand human lung physiology have led to much rewarding progress in the last century. The identification of the relevant mechanisms underlying several lung pathologies has been a vital part of this progress. In this context, we have witnessed that the quality assurance mechanisms of a cell play vital roles in maintaining a strict balance between cell survival and cell death, as well as to systematically respond to external and internal stress, thereby deciding the pathological consequences of various lung diseases. Such quality control already begins at the level of cellular organelles, namely, the endoplasmic reticulum (ER), mitochondria, the proteasome or the lysosome, but all these mechanisms converge into two major cellular surveillance systems: the ubiquitin–proteasome system (UPS) and the autophagy–lysosome pathway. We appreciate such studies in cellular, pre-clinical or clinical models of chronic lung diseases and encourage investigators to submit original research articles as well as review articles.

### Guest Editor

Dr. Poornima Mahavadi

Center for Interstitial and Rare Lung Diseases, Department of Internal Medicine, Justus-Liebig University Giessen, 35392 Giessen, Germany

### Deadline for manuscript submissions

closed (15 November 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/107780](https://mdpi.com/si/107780)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).